drugset / Trial / NCT05923905
Clinical Study to Evaluate the Efficacy and Safety of FB1006 in the Treatment of ALS Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized double-blind controlled exploratory clinical study to evaluate the efficacy and safety of FB1006 in the treatment of amyotrophic lateral sclerosis (ALS) patients.
Timeline
- Start
- 2023-01-18
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FB1006 | Unknown | 30 mg | — |
Indications
No indication recorded.